Key facts
- This page summarizes Jonathan E. Freeman's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 15 Sep 2025, 08:29.
Jonathan E. Freeman - 11 Sep 2025 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)
- Reporting relationship
- Director
- Issuer ticker
- PHIO
- Reported as of
- 11 Sep 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Sep 2025, 08:29:41 UTC
- Prior SEC filing
- 13 Sep 2024
- Next SEC filing
- 06 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa C. Carson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan E. Freeman filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 15 Sep 2025.
Change
- Previous filing in this sequence was filed on 13 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001708133
Primary reporting owner
Freeman Jonathan E
- Relationship
- Director
- Address
- C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA
- Signature
- /s/ Lisa C. Carson, Attorney-in-Fact
- Signature date
- 15 Sep 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHIO
transaction
Common Stock, $.0001 par value
Award
- Transaction value
- $0
- Shares
- +14,700
- Change %
- +1085%
- Price
- $0.000000
- Shares after
- 16,055
- Date
- 11 Sep 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
Footnote F2
Includes shares of common stock underlying unvested restricted stock units.
Footnote F3
The number of reported securities has been adjusted to reflect prior reverse stock splits.
SEC remarks
Exhibit 24 - Power of Attorney